Villa Bosch-Pcia. de Buenos Aire, Argentina

Gabriela I Aparicio

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gabriela I Aparicio: Innovator in Modified Human Erythropoietin

Introduction: Gabriela I Aparicio is a notable inventor based in Villa Bosch, Buenos Aires, Argentina. With expertise in the field of biochemistry, she has made significant contributions to the development of modified human erythropoietin, a vital protein with medical applications. Her innovative work addresses important aspects of erythropoietin's function and enhances its therapeutic potential.

Latest Patents: Gabriela I Aparicio holds one patent titled "Modified Human Erythropoietin." This invention describes a modified version of human erythropoietin that features an increased plasma half-life. It exhibits an erythropoietic activity of less than 0.5% compared to native erythropoietin, while retaining its neuroprotective and neuroplastic abilities. The invention incorporates mutations at specific binding sites of the homodimeric and heterodimeric receptors by adding consensus sites for N-glycosylation, thereby improving its effectiveness.

Career Highlights: Gabriela has collaborated with prestigious institutions, notably the National University of Litoral and the National Scientific and Technical Research Council (CONICET). Her academic background and research endeavors highlight her commitment to advancing scientific knowledge and innovation in her field.

Collaborations: Throughout her career, Gabriela has worked alongside esteemed colleagues, including Marcos Oggero-Eberhardt and Maria De Los Milagros Burgi-Fissolo. These collaborations have been invaluable in the development and refinement of her research projects and patents.

Conclusion: Gabriela I Aparicio exemplifies the transformative power of innovation in the realm of biochemistry. Her contributions to the field, particularly through her patent for modified human erythropoietin, demonstrate her dedication to enhancing medical therapies and improving patient care. Her work continues to inspire future advancements in biotechnology and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…